First Trust Advisors LP Purchases 31,645 Shares of Moderna, Inc. (NASDAQ:MRNA)

First Trust Advisors LP grew its holdings in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 5.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 668,467 shares of the company's stock after purchasing an additional 31,645 shares during the period. First Trust Advisors LP owned about 0.17% of Moderna worth $27,795,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the company. Wilmington Savings Fund Society FSB raised its holdings in shares of Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock worth $33,000 after buying an additional 587 shares in the last quarter. Venturi Wealth Management LLC raised its holdings in shares of Moderna by 286.2% during the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock worth $37,000 after buying an additional 664 shares in the last quarter. Compass Planning Associates Inc acquired a new position in shares of Moderna during the 4th quarter worth $37,000. Crowley Wealth Management Inc. acquired a new position in shares of Moderna during the 4th quarter worth $41,000. Finally, MassMutual Private Wealth & Trust FSB raised its holdings in shares of Moderna by 58.2% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock worth $44,000 after buying an additional 389 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company's stock.

Wall Street Analyst Weigh In

MRNA has been the subject of a number of recent research reports. Leerink Partners lowered their target price on Moderna from $31.00 to $27.00 and set an "underweight" rating for the company in a report on Thursday, January 16th. William Blair reaffirmed a "market perform" rating on shares of Moderna in a report on Thursday, April 17th. Bank of America lowered their target price on Moderna from $41.00 to $34.00 and set an "underperform" rating for the company in a report on Tuesday, February 11th. Barclays cut Moderna from an "overweight" rating to an "equal weight" rating and lowered their target price for the stock from $111.00 to $45.00 in a report on Tuesday, February 18th. Finally, Berenberg Bank upped their target price on Moderna from $33.00 to $42.00 and gave the stock a "hold" rating in a report on Thursday, January 16th. Four research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Moderna currently has a consensus rating of "Hold" and an average price target of $58.70.

Moderna Stock Up 1.3 %

NASDAQ:MRNA traded up $0.36 on Tuesday, hitting $27.82. The stock had a trading volume of 5,238,914 shares, compared to its average volume of 7,348,912. The business's fifty day moving average is $30.03 and its 200 day moving average is $38.15. The company has a market cap of $10.76 billion, a PE ratio of -3.00 and a beta of 2.23. Moderna, Inc. has a 52 week low of $23.15 and a 52 week high of $170.47.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.